Nitrous oxide-induced myeloneuropathy: a case series.

Humans Nitrous Oxide / adverse effects Substance-Related Disorders Spinal Cord Diseases / chemically induced Paresthesia
B12 deficiency clinical neurology myelopathy neuropathy

Journal

Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R

Informations de publication

Date de publication:
09 2023
Historique:
received: 19 01 2023
accepted: 03 04 2023
medline: 16 8 2023
pubmed: 31 5 2023
entrez: 30 5 2023
Statut: ppublish

Résumé

Nitrous oxide (N We describe 119 patients with N Paraesthesia was the presenting complaint in 85% of cases, with the lower limbs more commonly affected than the upper limbs. Gait ataxia was common, and bladder and bowel disturbance were frequent additional symptoms. The mid-cervical region of the spinal cord (C3-C5) was most often affected on MRI T2-weighted imaging. The number of N Preventable neurological harm from N

Sections du résumé

BACKGROUND
Nitrous oxide (N
METHODS
We describe 119 patients with N
RESULTS
Paraesthesia was the presenting complaint in 85% of cases, with the lower limbs more commonly affected than the upper limbs. Gait ataxia was common, and bladder and bowel disturbance were frequent additional symptoms. The mid-cervical region of the spinal cord (C3-C5) was most often affected on MRI T2-weighted imaging. The number of N
CONCLUSIONS
Preventable neurological harm from N

Identifiants

DOI: 10.1136/jnnp-2023-331131 PMID: 37253616 PMC: PMC10447413
pubmed: 37253616
pii: jnnp-2023-331131
doi: 10.1136/jnnp-2023-331131
pmc: PMC10447413
doi:

Substances chimiques

Nitrous Oxide K50XQU1029

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

681-688

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: DM leads a medical student-run unpaid campaign - ‘N2O: Know The Risks’ - which provides educational teaching sessions on the risks of nitrous oxide in East London.

Références

Eur J Neurol. 2021 Dec;28(12):3938-3944
pubmed: 34427020
Front Neurol. 2021 Feb 02;12:626174
pubmed: 33603713
Am J Health Syst Pharm. 2015 Jun 1;72(11):952-7
pubmed: 25987690
Lancet. 2014 Oct 18;384(9952):1446-54
pubmed: 25142708
Neuropsychiatr Dis Treat. 2020 Nov 23;16:2817-2825
pubmed: 33262596
Iran J Neurol. 2013;12(3):111-3
pubmed: 24250916
Nat Rev Dis Primers. 2017 Jun 29;3:17040
pubmed: 28660890
J Clin Med. 2019 Apr 23;8(4):
pubmed: 31018613
Pract Neurol. 2023 Jun;23(3):222-228
pubmed: 36813556
Global Spine J. 2019 May;9(3):331-337
pubmed: 31192102
Lancet. 1978 Dec 9;2(8102):1227-30
pubmed: 82736
Int J Drug Policy. 2022 Feb;100:103519
pubmed: 34753046
Clin Neurol Neurosurg. 2018 Oct;173:163-168
pubmed: 30144777
J Thromb Thrombolysis. 2022 Nov;54(4):686-695
pubmed: 35759070
Pract Neurol. 2015 Jun;15(3):207-9
pubmed: 25977272
Am J Emerg Med. 2012 Jul;30(6):1016.e3-6
pubmed: 22169583
Front Psychiatry. 2018 Jan 22;8:312
pubmed: 29403400
Anesthesiology. 2019 Nov;131(5):1063-1076
pubmed: 31490294
J Neurosurg Anesthesiol. 2022 Jul 1;34(3):306-312
pubmed: 33901062
J Neurol. 2018 May;265(5):1089-1095
pubmed: 29502317

Auteurs

Devan Mair (D)

Queen Mary University of London Barts and The London School of Medicine and Dentistry, London, UK.
Barts Health NHS Trust, London, UK.
ORCID: 0000-0002-9461-7014

Alvar Paris (A)

Barts Health NHS Trust, London, UK.
Preventive Neurology Unit, Centre for Prevention, Diagnosis and Detection, Faculty of Medicine and Dentistry, Queen Mary University of London, Wolfson Institute of Population Health, London, UK.

Safiya A Zaloum (SA)

Queen Mary University of London Barts and The London School of Medicine and Dentistry, London, UK.
Barts Health NHS Trust, London, UK.

Laura M White (LM)

Manchester Centre for Clinical Neuroscience, Northern Care Alliance NHS Foundation Trust, Salford, UK.

Katherine C Dodd (KC)

Manchester Centre for Clinical Neuroscience, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Lydia Becker Institute for Immunology and Inflammation, Division of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester Faculty of Biology Medicine and Health, Manchester, UK.

Christina Englezou (C)

Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Department of Neurology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.

Farhin Patel (F)

Queen Mary University of London Barts and The London School of Medicine and Dentistry, London, UK.

Siraj Abualnaja (S)

Queen Mary University of London Barts and The London School of Medicine and Dentistry, London, UK.

James B Lilleker (JB)

Manchester Centre for Clinical Neuroscience, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester Faculty of Biology Medicine and Health, Manchester, UK.

David Gosal (D)

Manchester Centre for Clinical Neuroscience, Northern Care Alliance NHS Foundation Trust, Salford, UK.

Tom Hayton (T)

Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Di Liang (D)

Department of Neurosciences, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Holger Allroggen (H)

Department of Neurosciences, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Mark Pucci (M)

University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Stephen Keddie (S)

Barts Health NHS Trust, London, UK.
MRC Centre for Neuromuscular Disease and Department of Molecular Neuroscience, University College London Hospitals NHS Foundation Trust National Hospital for Neurology and Neurosurgery, London, UK.
ORCID: 0000-0002-2102-6053

Alastair J Noyce (AJ)

Barts Health NHS Trust, London, UK a.noyce@qmul.ac.uk.
Preventive Neurology Unit, Centre for Prevention, Diagnosis and Detection, Faculty of Medicine and Dentistry, Queen Mary University of London, Wolfson Institute of Population Health, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Nitrous oxide-induced myeloneuropathy: a case series.
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Oxydes › Oxydes d'azote › Protoxyde d'azote › Nitrous oxide-induced myeloneuropathy: a case series.
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Nitrous oxide-induced myeloneuropathy: a case series.
questionsmedicales.fr › Maladies du système nerveux › Maladies du système nerveux central › Maladies de la moelle épinière › Nitrous oxide-induced myeloneuropathy: a case series.
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Troubles sensitifs › Troubles somatosensoriels › Paresthésie › Nitrous oxide-induced myeloneuropathy: a case series.